Results 181 to 190 of about 2,758 (199)

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

Lancet Respiratory Medicine,the, 2023
Simon Bond, Marianna Nodale, Jonathan Underwood   +2 more
exaly  

Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

Lancet Haematology,the, 2023
Morag Griffin, Jun-ichi Nishimura, Antonio Maria Risitano   +2 more
exaly  

PNH: Neue Daten zu Ravulizumab

InFo Hämatologie + Onkologie, 2023
openaire   +1 more source

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

Pediatric Nephrology, 2020
Stephan Ortiz, Larry A Greenbaum
exaly  

Ravulizumab auch gegen NMOSD wirksam

InFo Neurologie + Psychiatrie, 2023
openaire   +1 more source

Ravulizumab in patients with generalised myasthenia gravis

Medicom Conference Report AAN 2022, 2022
Tuan Hoang Vu, Michiel Tent
openaire   +1 more source

Keine komplementvermittelten Durchbruchhämolysen mit Ravulizumab

Transfusionsmedizin, 2021
openaire   +1 more source

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Journal of Medical Economics, 2020
Yan Wang, Karissa M Johnston, Evan Popoff   +2 more
exaly  

Ravulizumab effective in AQP4+ NMOSD

Medicom Conference Report AAN 2023, 2023
openaire   +1 more source

Meningococcal vaccine conjugate/ravulizumab

Reactions Weekly, 2019
openaire   +1 more source